Combined Therapy Significantly Reduces Melanoma Recurrence and Mortality

A recent study from NYU Langone Health indicates that a combination of a vaccine and a drug, both targeting cancer cells via the immune system, has sustained a 49% reduction in melanoma recurrence and death over five years. This consistent improvement was observed after surgical removal of tumors. The findings offer promising long-term outcomes for skin cancer patients.